Cipher Pharmaceuticals has launched Epuris (isotretinoin) capsules for the treatment of severe acne in patients aged 12 years and more in Canada.
Available in 10mg, 20mg, 30mg, and 40mg oral capsules, the novel brand formulation of the acne medication isotretinoin facilitates reliable absorption and flexible dosing that both patients and physicians need, claimed the company.
With 83% greater absorption under fasted conditions, Epuris is bioequivalent to Accutane under high fat fed context.
Cipher CEO Larry Andrews said Epuris is launched as a new treatment option for Canadian dermatologists and their patients who suffer from severe acne.
"This represents an important milestone on the path to building Cipher's commercial portfolio and franchise in Canada," Andrews added.
"We expect this will be the first of a number of products we introduce, beginning in Dermatology and, over time, in other specialty markets."
